Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (US20090324638) LIVE BACTERIAL VACCINE

Office : United States of America
Application Number: 12304634 Application Date: 12.06.2006
Publication Number: 20090324638 Publication Date: 31.12.2009
Publication Kind : A1
Prior PCT appl.: Application Number:US07013753 ; Publication Number: Click to see the data
IPC:
A61K 39/02
A61P 31/00
A61P 31/04
C12N 1/21
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1
Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor
20
Bacteria; Culture media therefor
21
modified by introduction of foreign genetic material
Applicants: Biopeptides Corp.
Lactrys Octrooi BV
Inventors: Dattwyler Raymond J.
Gomes-Solecki Maria J.C.
Seegers Jozef F.M.L.
Agents: VENABLE LLP
Priority Data:
Title: (EN) LIVE BACTERIAL VACCINE
Abstract: front page image
(EN)

The present invention relates, e.g., to a Lactobacillus bacterium, which (1) expresses a recombinant polypeptide containing a lipoprotein signal sequence from the OspA protein of Borrelia burgdorferi, or an active variant of the leader sequence, operably linked to one or more heterologous polypeptide(s) of interest and/or (2) which comprises an expressible polynucleotide encoding a recombinant polypeptide, wherein the polynucleotide encodes a lipoprotein signal from the OspA protein of Borrelia burgdorferi, or an active variant thereof, which is operably linked to one or more heterologous polypeptide(s) of interest. In one embodiment, the heterologous polypeptide is from Yersinia pestis, the etiologic agent of plague. In another embodiment, the heterologous polypeptide is from Borrelia burgdorferi, the etiologic agent of Lyme disease. Also described are immunogenic compositions, such as live bacterial vaccines, comprising the bacterium; methods for eliciting an immune response against the polypeptide using the bacterium; and kits comprising the bacterium.


Also published as:
EP2035036CA2687468WO/2008/063240